Prof. Isabelle SALMON, Ph. D., Pathology Department, Erasme Hospital, ULB
Isabelle Salmon obtained a MD degree in 1985 and was certified specialist in Pathology in 1991. She obtained an “Agrégation de l'Enseignement Superieur” degree (Ph.D. degree and qualification for university professorship) in Medical Sciences in 1993 from the Université Libre de Bruxelles (ULB). Since 1999, she is the head of the Pathology Department of the ULB Erasme Hospital which manages the diagnostic activity for all the hospital services including polyclinics. She teaches pathology at the ULB School of Medicine. Her research interests include glioma biology and the identification of biomarkers in the context of different non-tumoral and tumoral pathologies, with a particular focus on neuropathology. She published more than 250 articles in peer reviewed journals. She is SBAP-BVAP and BWP chairperson and is member of numerous scientific (national and international) societies. Together with Christine Decaestecker she created DIAPATH, an interfaculty research center (Faculty of Applied Sciences and School of Medicine) from ULB. DIAPATH’s activities focus on the identification of diagnostic, prognostic and theragnostic biomarkers as well as on the analysis and characterization of animal models, using a multidisciplinary and integrated approach based on histology, immunohistochemistry, image and data analysis.
Prof. Christine DECAESTECKER, Ph. D., LISA, ULB
Christine Decaestecker obtained a PhD degree in Pure Science (Mathematics) in 1991 and an “Agrégation de l'Enseignement Superieur” degree (qualification for university professorship) in 1997 from the Université Libre de Bruxelles (ULB). She is Senior Research Associate with the “Fonds National de la Recherche Scientifique” (Belgian national funds for scientific research, Brussels, Belgium). She is a member of the Laboratory of Image Analysis and Synthesis (LISA) from the ULB Faculty of Applied Sciences and teaches data analysis and machine learning. She also is the chairperson of the biomedical engineering degree at the ULB Faculty of Applied Sciences. Her research interests include machine learning, pattern recognition and image analysis applied to biomedical fields (more particularly cell biology and clinical research). She has more than 150 publications in peer reviewed journals. Together with Isabelle Salmon she created DIAPATH, an interfaculty research center (Faculty of Applied Sciences and School of Medicine) from ULB. DIAPATH’s activities focus on the identification of diagnostic, prognostic and theragnostic biomarkers as well as on the analysis and characterization of animal models, using a multidisciplinary and integrated approach based on histology, immunohistochemistry, image and data analysis.
Kathy JAWORSKI : Ph.D.
Kathy Jaworski obtained her PhD degree in cell and molecular biology in 2001 from the University of Louvain La Neuve (UCL). Her research was focused on metabolic diseases (atherosclerosis, diabetes). After one year of research assistant at the same University, she obtained a postdoctoral fellowship of 5 years at the University of California Berkeley (UCB). She investigated the in vivo function of a novel adipose-enriched target gene (AdPLA). After, she worked for 4 years in neonatal adaptive immunity at the Institute for Medical Immunology (IMI Gosselies). She conducted in vitro and in vivo studies to evaluate the T follicular helper function in early life. She joined recently the Diapath unit (CMMI Gosselies). Her activities are focused on the identification and characterization of biomarkers in glioma biology.
Sauvage Sébastien, M. Sc.
Born in October, 1976 in Haine-Saint-Paul (Belgium), Sébastien Sauvage obtained his Master degree in chemistry in 2000 at the University of Mons, Belgium. He obtained his “D.E.A.” in molecular biology in 2002 at the same university. His “D.E.A.” was focused on the Fascioscapulohumeral dystrophy (FSHD). He studied the proteins profile by 2D SDS-PAGE of this disease and specially the expression of two proteins members of the DUX family (DUX4 and DUX4c) that are involved in the mechanism of this muscular dystrophy. After three years in Unibioscreen (oncology discovery & development specialized company) and two years in the Pathology Department of the ULB Erasme Hospital, he works now in the DIAPATH unit within The Center for Microscopy and Molecular Imaging (CMMI). He works on the development of immuno-histochemistry protocols and on the identification, characterization and validation of protein biomarkers.
Paul Barbot was born in 1985. He studied Computer Science and Software Engineering at EPITA in Paris from which he graduated with an Engineering title. He then moved to the Netherlands to work on CT/MR 3D visualisation software at Philips Healthcare. He is now working at the CMMI on image processing of pathology images.
- Automated immunohistochemistry system (Ventana Discovery XT)
- Slide scanner (Hamamatsu Nanozoomer C96000-01)
- Adult interfollicular tumour-initiating cells are reprogrammed into an embryonic hair follicle progenitor-like fate during basal cell carcinoma initiation Khalil Kass Youssef, Gaëlle Lapouge, Karine Bouvrée, Sandrine Rorive, Sylvain Brohée, Ornella Appelstein, Jean-Christophe Larsimont, Vijayakumar Sukumaran, Bram Van de Sande, Doriana Pucci, Sophie Dekoninck, Jean-Valery Berthe, Stein Aerts, Isabelle Salmon, Véronique del Marmol & Cédric Blanpain Nature Cell Biology 14, 1282–1294, (2012) doi:10.1038/ncb2628
- L. Ferdinande, C. Decaestecker, A. Mathieu, L. Verset, X. Moles Lopez, A.-M. Negulescu, T. Van Maerken, I. Salmon, C.A. Cuvelier, P. Demetter. Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. Br J Cancer 2012; 106(1): 141-147.
- X. Moles Lopez, O. Debeir, C. Maris, S. Rorive, I. Roland, M. Saerens, I. Salmon, C. Decaestecker. Clustering methods applied in the detection of Ki67 hot-spots in whole tumor slide images: an efficient way to characterize heterogeneous tissue-based biomarkers. Cytometry: Part A 2012 ; 81(9):765-75
- Marie Le Mercier, Delfyne Hastir, Xavier Moles Lopez, Nancy De Nève, Calliope Maris, Anne-Laure Trepant, Sandrine Rorive, Christine Decaestecker, Isabelle Salmon. A simplified approach for the molecular classification of glioblastomas. PLoS One. 2012;7(9):e45475.
- Mathieu A, Weynand B, Verbeken E, Da Silva S, Decaestecker C, Salmon I, Demetter P. Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer. Lung Cancer 2010;69:46-50. IF = 3.1.
- Rorive S, D'Haene N, Fossion C, Delpierre I, Abarguia N, Avni F, Decaestecker C, Salmon I. Ultrasound-guided fine-needle aspiration of thyroid nodules : stratification of malignancy risk using follicular proliferation grading, clinical and ultrasonographic features. Eur J Endocrinol 2010;162:1107-15. IF=3.5.
- Laurendeau I, Ferrer M, Garrido D, D'haene N, Ciavarelli P, Basso A, Vidaud M, Bieche I, Salmon I, Szijan I. Gene expression profiling of the Hedgehog signaling pathway in human meningiomas. Mol Med. 2010. Jul-Aug;16(7-8):262-70.
- Flamez D, Roland I, Berton A, Kutlu B, Dufrane D, Beckers MC, De Waele E, Rooman I, Bouwens L, Clark A, Lonneux M, Jamar JF, Goldman S, Maréchal D, Goodman N, Gianello P, Van Huffel C, Salmon I, Eizirik DL. A genomic-based approach identifies FXYD domain containing ion transport regulator 2 (FXYD2) gamma as a pancreatic beta cell-specific biomarker. Diabetologia 2010;53:1372-83. IF = 6.5.
- Pozdzik AA, Berton A, Schmeiser HH, Missoum W, Decaestecker C, Salmon IJ, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy revisited: a place for innate and adaptive immunity? Histopathology 2010;56:449-63. IF = 3.8.
- Rivas MN, Hazzan M, Weatherly K, Gaudray F, Salmon I, Braun MY. NK cell regulation of CD4 T cell-mediated graft-versus-host disease. J Immunol 2010;184:6790-8. IF = 5.6.
- Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Salmon I, Devière J, Van Laethem JL. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer 2010;15:116(22):5200-6.
- Maréchal R, De Schutter J, Nagy N, Demetter P, Lemmers A, Devière J, Salmon I, Tejpar S, Van Laethem JL. Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients. BMC Cancer 2010;10:340.
- Rorive S, Moles-Lopez X, Maris C, Trepant A-L, Sauvage S, Sadeghi N, Roland I, Decaestecker C, Salmon I. TIMP-4 and CD63: New Prognostic Biomarkers in Human Astrocytomas. Mod Pathol. 2010 Oct;23(10):1418-28.
- Decaestecker C, et al. Requirements for the valid quantification of immunostains on tissue microarray materials using image analysis. Proteomics 2009;9:4478-94.
- D’Haene N, et al.. Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas. Br J Haematol 2008;140:402-10.
- D’Haene N, et al. The differential expression of Galectin-1 and Galectin-3 in normal lymphoid tissue and non-Hodgkin’s and Hodgkin’s lymphomas. Int J Immunopathol Pharmacol 2005;18:431-43.
- Mathieu A, et al. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi. Cancer 2004;101:1908-18
1. Custom services: pathology, histology, immunohistochemistry (IHC)
2. Imaging: macro/microscopy, whole slide scanning, image analysis (histology, staining, IHC)
3. Screening: drug target, protein expression
4. Validation: animal model, biomarker, antibody, companion diagnostics
DIAPATH is a multidisciplinary and inter-faculty unit which offers an integrated solution to histological analysis as well as the identifi cation, characterization and validation of protein biomarkers. The methodology is based on standardized laboratory procedures and quality controls ensuring reproducibility and traceability. It involves the following technologies : (i) macroscopic analysis (organs, tissues, etc.), (ii) microscopic histological analysis (using haematoxilin-eosin and special staining), (iii) tissue microarray (TMA) and cell-block (for cell line analysis), (iv) immunohistochemistry (IHC), (v) histological and TMA slide scanning (digitalization) and image analysis, (vi) statistical data analysis.
IHC has the advantage to preserve tissue morphology and thus antigen location at histological and cell levels. By simultaneously processing thousands of samples, the TMA technology allows standardized screening of protein expression using IHC and thus provides a very effi cient way for biomarker validation. Slide scanning and image analysis enable archiving and quantitative and objective immunostaining characterization. Finally, data analysis allows to statistically validate and quantitatively compare biomarkers.
See the poster: Poster_CMMI_-_Diapath_-_compressed.pdf